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End TB strategyA B S T R A C T
Current World Health Organisation targets calling for an end to the global tuberculosis (TB)
epidemic by 2035 require a dramatic improvement in current case-detection strategies. A
reliance on passive case finding (PCF) has resulted consistently, in over three million infec-
tious TB cases per year, being missed by the health system, leading to ongoing transmis-
sion of infection within families and communities. Active case finding (ACF) for TB has
been recognized as an important complementary strategy to PCF, in order to diagnose
and treat patients earlier, reducing the period of infectiousness and therefore transmission.
ACF may also achieve substantial population-level TB control. Local TB epidemiology and
the resources available in each setting will influence which populations should be
screened, and the types of ACF interventions to use for maximal impact. TB control pro-
grams should begin with the highest risk groups and broaden their activities as resources
allow. Mathematical models can help to predict the population-level effects and the cost-
effectiveness of a variety of ACF strategies on different risk populations.
 2016 Asian-African Society for Mycobacteriology. Production and hosting by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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Introduction Active case finding versus passive case findingIn the past two decades, the Directly Observed Treatment
Short-Course (DOTS) strategy and the subsequent Stop TB
(DOTS expansion) strategy, recommended by the World
Health Organisation (WHO), saved more than five million
lives [1]. However, total case numbers continue to rise and
tuberculosis (TB) remains the leading infectious cause of
death worldwide [2]. The WHO launched the End TB Strategy
in 2015 with the ambitious goal of ending the global TB epi-
demic [3]. Targets include a 90% reduction in TB incidence
and 95% reduction in TB deaths by 2035, compared to 2015.
‘‘Bending the epidemiological curve” of TB incidence and
mortality to meet these targets, will require improved case
detection to ensure early disease diagnosis, improve individ-
ual patient outcomes, and limit ongoing transmission.
In the majority of TB endemic settings worldwide, the sta-
tus quo for TB case finding is based on ‘‘passive case finding”
(PCF). This relies upon a patient with active TB experiencing
symptoms serious enough to seek health care and a health-
care system capable of correctly diagnosing the patient’s con-
dition. [4] However, this strategy, as shown consistently in
prevalence surveys [5,6], is grossly inadequate to detect the
substantial burden of undiagnosed TB in the community. It
is estimated that in 2014, more than 3.5 million people who
developed TB (one-third of all cases) were ‘‘missed” by the
health system [2]. This massive case detection gap culmi-
nates in late disease presentation, with poor disease out-
comes, and undiagnosed infectious cases continuing to
spread infection within families and communities.
The term ‘‘active case finding” (ACF) includes any methods
for TB identification that does not rely on patients presenting
to the healthcare system of their own accord [7]. The objec-
tives of ACF are to diagnose and treat patients earlier, thereby
reducing negative treatment outcomes, sequelae, and socioe-
conomic consequences, as well as reducing the period of
infectiousness and therefore transmission [4]. ACF has been
increasingly recognised as an important complementary
strategy to PCF in high-prevalence settings in order to over-
come the gaps in TB detection and treatment. This need has
also been recognized by international donors, with initiatives
such as TB REACH established to support innovative
approaches to increasing TB case detection [8]. Although
two WHO guidelines, systematic screening [4] and household
contact investigations [9], provide some guidance to ACF in
resource limited settings, designing and implementing inter-
ventions that target the most appropriate populations, and
utilise feasible and cost-effective strategies, may be difficult
for national TB control programs (NTP) already struggling to
manage the existing burden of known disease.
In this review, we compare the additional individual and
population-level benefits of ACF with those of PCF, consider
pragmatic and economic factors relevant to ACF implementa-
tion in resource-limited settings, and highlight future
research needs and priorities.The principle objective of ACF is to find and treat cases of
active TB that would otherwise not have been diagnosed at
this time, using strategies that are in keeping with available
resources. An important distinction between ACF and PCF is
that the former is a screening intervention initiated by health
services, as opposed to the latter, which is initiated by symp-
tomatic individuals presenting to health-care. In general, ACF
activities are additive to PCF. Consequently, the diagnostic
algorithms and measures of success used in ACF may differ
from those used for PCF. The population targeted for ACF is
typically larger, and the prevalence of disease (or pretest prob-
ability) is lower. This results in a higher number needed to
screen, to diagnose one TB patient, compared to the PCF
context.
ACF for TB generally begins with an initial screening step
followed by confirmatory testing. Initial screening may com-
prise of one or a combination of symptom reporting or chest
radiography, and if either are positive, a confirmatory micro-
biological test, such as smear microscopy, or a molecular test
e.g. Xpert MTB/RIF [4]. Ideally, the confirmatory test should be
rapid, hence Mycobacterium tuberculosis (MTB) culture is a less
feasible option, unless the health system in place has suffi-
cient capacity to follow-up screened patients [4].
However, the use of symptoms or chest X-ray as the initial
screening step has important limitations. Prevalence surveys
have shown consistently that the majority of undiagnosed TB
patients in the community lack typical symptoms of TB and a
large proportion have no symptoms at all [10–12]. Further-
more, while chest radiography is more sensitive than using
a symptom-based approach alone, this can be logistically dif-
ficult in many rural and remote settings. Xpert MTB/RIF used
up-front as a primary screening tool (i.e., regardless of symp-
toms reported or chest X-ray findings), has been shown to be
feasible and improve case detection in certain high risk pop-
ulations, such as people living with HIV (PLHIV) [13,14], and
also in ACF conducted in the general community [15]. While
this approach may overcome some limitations of traditional
TB screening, the feasibility and cost-effectiveness of this
strategy in a programmatic setting is yet to be determined.
One argument against ACF it that it merely detects disease
earlier, but does not substantially alter individual patient out-
comes. However, diagnosing and treating TB disease earlier is
likely to have a substantial impact on TB transmission,
decreasing the long term trajectory of TB in a population,
and subsequently reducing the cost of TB control overall
[16]. It is important however, when evaluating the
population-level effects and the cost-effectiveness of ACF, to
consider its impact over a longer time frame (e.g., a 20-year
time horizon), as short-term assessments can dramatically
underestimate longer- term gains of ACF [16]. Table 1 lists out-
come measures that should be considered when evaluating
the benefit of ACF, as well as the other key characteristics of
ACF compared to PCF for TB.
Table 1 – Characteristics of active compared to passive case finding for TB.
Characteristic Considerations for active case finding
Population evaluated Less reported symptoms
Earlier stage of disease
Lower bacillary (MTB) load
Reduced health seeking behaviour
May be less likely to accept and complete treatment
More health care access and socioeconomic factors to consider
Prevalence of disease Usually lower
Screening algorithm The primary screening tool used should be:
– Rapid and simple to perform
– Sensitive to detect low organism load/early disease
– Appropriate to the resources available
– Adapted for the specific context and relevant target populations
Overall case detection should identify:
– Infectious patients as early as possible
– Detect active TB before serious complications develop
– Maximize ‘‘value for money” with the available resources
Outcome measures Focus on the added value of ACF such as:
– Reduced morbidity and mortality (less advanced disease);
– May experience initial increase in TB incidence with enhanced detection
– Decreased time to treatment initiation
– Improved treatment outcomes
– Reduced TB transmission; measured as prevalence of TB infection in young children
– Reduced active TB; measured as TB disease prevalence in the community
Should incorporate population level effects and cost-effectiveness estimates using a
long-term time frame
MTB =Mycobacterium tuberculosis; ACF = active case finding.
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yield target populations versus community-wide
interventions
Factors that influence the choice of which populations should
be targeted for ACF include: TB prevalence, TB risk (e.g.,
comorbidities and socioeconomic factors), accessibility,
acceptability (amongst individuals in the population and
health care workers), and the infrastructure and resources
available.
In the ‘‘systematic screening for active TB” guidelines, the
WHO strongly recommend ACF for PLHIV, household contacts
of active TB patients, and workers exposed to silica [4]. Condi-
tional recommendations (based on expert opinion and depen-
dent on local TB epidemiology and resource factors), are given
for other risk groups such as prisoners, those with untreated
fibrotic lesions on chest X-ray; those seeking health care and
selected risk groups where the TB prevalence isP0.1%; popu-
lations where the TB prevalence is P1%; or those with poor
access to health-care [4]. Clinical groups with a higher risk
of developing TB (and poorer treatment outcomes) that may
benefit from ACF include those who are underweight, mal-
nourished, diabetic, have alcohol dependence, smoke, have
chronic renal failure, or immunosuppression [4,17]. Homeless
people, those living in slums, and other deprived communi-
ties generally have poorer access to health-care, a higher risk
of TB transmission in some settings, and may also benefit
greatly from ACF interventions [18–20].
Before the 1960s, mass chest radiography was the primary
form of ACF inmany industrialized countries [21]. However, intheir ninth report in 1974, the WHO expert committee on
tuberculosis recommended that ‘‘the policy of indiscriminate
TB case-finding by mobile mass radiography should now be
abandoned”, citing evidence of the inefficiency, low yield,
and high cost of mass radiography [22]. Since this recommen-
dation, screening of populations for TB generally has been
avoided, other than for selected high-risk groups. Instead,
high prevalence countries have been encouraged to focus their
resources on optimizing existing diagnostic and treatment
services. However, this narrow focus on selected high-risk
groups has been unable to reach the majority of undiagnosed
cases in the community and, despite substantial investment
in PCF, has only achieved a global decline in TB incidence of
2% per year [2]. This figure needs to increase to 10% per year
by 2025, to achieve TB elimination targets [3]. Therefore, it is
imperative that broader screening strategies that will achieve
the desired epidemiological impact are considered.
Few randomized trials that have assessed the effective-
ness of ACF in a community-wide setting. Four randomized
controlled trials (RCTs) have been performed in Africa, with
mixed results. A cluster RCT conducted in Zimbabwe (the
DETECTB study) [23] evaluated an intervention of six rounds
of six monthly screening for adults with P2 weeks of cough,
to over 100,000 participants using either mobile vans or
door-to-door visits. The study found a decline in disease
prevalence from 6.5 to 3.7 per 1000 adults (risk ratio 059,
95% CI 040–089, p = 0.0112) at the end of, compared to before,
the intervention. In contrast, a large community randomized
trial of active case-finding among almost 45,000 participants
in Zambia and the Western Cape of South Africa (the ZAM-
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[24]. The study compared two enhanced case finding inter-
ventions: community mobilization and promotion of sputum
smear examination; and combined TB-HIV household-level
activities. Neither intervention led to a reduction in the com-
munity prevalence or incidence of TB [24]. While these two
trials yielded different effects on disease prevalence, the
actual interventions used in these two studies differed
considerably.
Two additional RCTs of community-wide ACF studies in
rural southern Ethiopia [25,26] implemented periodic educa-
tion about TB symptoms, by community workers in periph-
eral health facilities, and encouraged symptomatic
individuals to seek health-care. One study found the inter-
vention improved case detection rates, compared to passive
case finding [25], whereas the other found a reduction in time
to diagnosis, but not the extent of case finding for smear pos-
itive TB [26].
What active case finding approach is optimal?
ACF for TB is likely to be feasible to some degree in all set-
tings; however, determining the most appropriate strategy
for each setting requires careful planning and consideration.
The most suitable approach will depend on the resources
available and the local TB epidemiology. NTPs should start
with a narrow focus (e.g., highest risk groups) and broaden
as resources allow. Baseline information required includes
high quality surveillance data such as prevalence rates, inci-
dence rates, and transmission ‘hot spots’. Mathematical mod-
elling can help predict the population level impact, cost-
effectiveness and optimal duration and frequency for specific
ACF interventions [16,27–29]. A web-based modeling tool,
developed by Nishikori [30], can be used to compare cost-
effectiveness parameters for different diagnostic algorithms
when applied to different risk populations [30].
Novel strategies involving community workers, volun-
teers, mobile phone technology, or the private sector to imple-
ment ACF activities [25,31], may improve the efficiency and
feasibility of ACF on a broader scale. Integrating ACF into
existing health-care services is also important to optimize
resources and achieve sustainability [32]. Adequate diagnostic
and treatment facilities, with the capacity for scale-up, are
crucial to avoid treatment delays and loss to follow-up. Lastly,
additional treatment support should be considered for
patients diagnosed via ACF, given that they may be minimally
symptomatic and their failure to initiate health care contact
may indicate reduced ‘‘readiness” for treatment. These
patients may also be burdened with socioeconomic factors
that make them more likely to fail to start, or be noncompli-
ant with treatment [33,34].
Research gaps and priorities
While there is consensus on the effectiveness of ACF in cer-
tain high-risk groups such as PLHIV and household contacts
[4], major research gaps remain. Whether ACF leads to better
treatment outcomes, substantially reduces transmission, or
has a beneficial impact on the longer-term epidemiology ofTB, remains unknown. We also do not know what strategies
are most effective in different settings, or, how frequently
and for how long ACF interventions need to be performed.
As the prevalence of disease decreases, ACF is likely to appear
less cost-effective (per case diagnosed) but will be important
to sustain long-term declines in incidence to achieve TB elim-
ination targets.
Further operational and public health research with appro-
priate impact evaluation, together with mathematical and
economic modeling, will be greatly beneficial in answering
some of these questions. Careful monitoring and evaluation
of all current and future ACF activities is also essential. Better
screening tools will also facilitate up-scaling of ACF strate-
gies. A sensitive, portable, low-cost, point-of-care test will
revolutionize TB screening, improving the efficiency, feasibil-
ity, and cost-effectiveness of all screening interventions.
Conclusion
Current passive TB case finding approaches are insufficient to
meet ambitious TB elimination targets, especially in endemic
areas where the bulk of the ‘‘missing 3.5 million cases” reside
[2]. Until new breakthroughs in disease prevention occur, sig-
nificant improvements in case detection will be essential if
the global TB epidemic is to be overcome. ACF interventions
are likely to be feasible in all settings, but the scale and focus
of these interventions will need to be contextualized and will
inevitably be limited by available resources. When designing
an ACF strategy, TB control programs should begin with easily
identifiable high-risk target groups and then widen their
scope of activities as resources allow. Further research is
imperative to determine the most feasible and cost-effective
ACF approaches in different settings.
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